Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:ACGN

Aceragen (ACGN) Stock Price, News & Analysis

Aceragen logo

About Aceragen Stock (NASDAQ:ACGN)

Advanced Chart

Key Stats

Today's Range
$0.38
$0.38
50-Day Range
$0.38
$0.90
52-Week Range
$0.36
$16.00
Volume
N/A
Average Volume
N/A
Market Capitalization
$3.20 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Aceragen, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for rare pulmonary and rheumatic diseases in the United States. Its clinical development pipeline includes ACG-701, which is in Phase 2 clinical trial for cystic fibrosis pulmonary exacerbations, as well as for melioidosis; and ACG-801 for farber disease. Aceragen, Inc. has a collaboration and option agreement with Scriptr Global, Inc. to identify, research, and develop gene therapy candidates for the treatment, palliation, diagnosis, or prevention of myotonic dystrophy type 1 and Friedreich's Ataxia. The company was formerly known as Idera Pharmaceuticals, Inc. and changed its name to Aceragen, Inc. in January 2023. Aceragen, Inc. was incorporated in 1989 and is headquartered in Exton, Pennsylvania.

Receive ACGN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aceragen and its competitors with MarketBeat's FREE daily newsletter.

ACGN Stock News Headlines

ACGN - Aceragen, Inc.
The End of Elon Musk…?
The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, and he's been proven right time and time again. And now, while the media focuses on Tesla's "demise," he's uncovered an AI breakthrough that's about to make Elon's doubters eat their words yet again. According to his research, if you listen to the media and miss out on Elon's newest breakthrough, it's going to cost you the fortune of a lifetime.
Aceragen, Inc. to Delist from The Nasdaq Stock Market
Aceragen: Q1 Earnings Snapshot
See More Headlines

ACGN Stock Analysis - Frequently Asked Questions

Based on aggregate information from My MarketBeat watchlists, some other companies that Aceragen investors own include Agenus (AGEN), Altamira Therapeutics (CYTO), Alimera Sciences (ALIM), Alpine Summit Energy Partners (ALPS), Angion Biomedica (ANGN), AirMedia Group (ANTE) and Aptorum Group (APM).

Company Calendar

Today
6/30/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED-BIOMED/GENE
Sub-Industry
N/A
Current Symbol
NASDAQ:ACGN
Employees
26
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$4.86 million
Price / Cash Flow
N/A
Price / Book
N/A

Miscellaneous

Free Float
6,196,000
Market Cap
$3.20 million
Optionable
Not Optionable
Beta
N/A
These 7 Stocks Will Be Magnificent in 2025 Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

This page (NASDAQ:ACGN) was last updated on 6/30/2025 by MarketBeat.com Staff
From Our Partners